European ADHD Guideline Group (EAGG)

European ADHD Guideline Group (EAGG)

The European ADHD Guidelines Group is a part of EUNETHYDIS set up to serve “the provision of evidence based clinical recommendations”. It therefore seeks to apply reliable scientific knowledge to help decision-makers, service users and practitioners in making well-informed judgements about how to improve the management of people affected by ADHD.

This over-riding goal involves making reviews, recommendations and guidance, and identifying gaps in the science base. It does so, in the general spirit of EUNETHYDIS, by acting as a co-operative group of scientific and clinical disciplines, where knowledge is disseminated in an atmosphere of trust, loyalty, and mutual respect. It will maintain high ethical standards in its activities.

EAGG Members

• Prof. Dieter Baeyens (Belgium)

  Research Unit Parenting and Special Education, Faculty of Psychology and Educational Sciences, KU Leuven, Belgium

  
  https://ppw.kuleuven.be/pserg/psergstaff/00062782
  
  

  Work and interests

  Dieter Baeyens is associate professor at the research unit Parenting and Special Education of KU Leuven. He is a registered clinical psychologist and behavior therapist. His research consists of two research lines aiming to develop and test interventions in health care and educational settings. His first research line focuses on the role of contextual factors (e.g. parenting, teacher-student interactions) in the development of executive functions in children and adolescents with and without ADHD, across different cultures. A second research line focuses on transitional care and intervention studies for individuals with ADHD and autism spectrum disorder in young adulthood (e.g., effect of reasonable accommodations, guidelines for transitional care). In his research, Baeyens combines a wide range of methods and designs: meta-analysis and –regression, experiments, intervention research (microtrials, RCT), psychometric studies for questionnaire development, and mixed-methods approaches. The valorization of his work includes development of ADHD questionnaires, intervention manuals (e.g., CBT for adults with ADHD) and books for professionals. Baeyens is chair of the Social and Societal Ethics Committee of KU Leuven. He is also the former coordinator of the section Special Educational Needs of the European Association for Research on Learning and Instruction (EARLI) (2015-2019). He is current member of the advisory board of ZitStil, the Flemish expertise center on ADHD, and of ICF Belgium. As an active member of the European Adult ADHD Network, he co-authored the European consensus statement on adult ADHD (2019). He co-heads with Saskia van der Oord the ADHD team of PraxisP, the intervention center of the Faculty of Psychology and Educational Sciences of KU Leuven.

  Declaration of potential conflict of interests

  N/A

• Prof. Tobias Banaschewski (Germany)

  Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim

  
  https://www.zi-mannheim.de/en/research/departments-research-groups-institutes/child-adolescent-psychiatry-psychotherapy-e.html
  https://www.zi-mannheim.de/en/patient-care/department-child-adolescent-psychiatry-psychotherapy.html
  
  

  Work and interests

  Tobias Banaschewski MD, PhD, is Professor of Child and Adolescent Psychiatry at the Medical Faculty Mannheim of the University of Heidelberg, Medical Director of the Department of Child and Adolescent Psychiatry of the Central Institute of Mental Health (CIMH), as well as and Deputy Director of the CIMH in Mannheim, Germany. Dr. Banaschewski studied psychology and medicine at the University of Marburg in Germany. He worked as Clinical Assistant in Adult Psychiatry in Marburg and as Clinical and Research Assistant in Child & Adolescent Psychiatry at the University of Göttingen.

  Declaration of potential conflict of interests

  12.08.2021
  During the last three years TB served in an advisory or consultancy role for ADHS digital, Infectopharm, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Roche, and Takeda.
  He received conference support or speaker’s fee by Medice and Takeda.
  He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press.

• Prof. Sven Bölte (Sweden)

  Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Department of Women’s and Children’s Health, Karolinska Institutet;
  Child and Adolescent Psychiatry, Stockholm Health Care Services, Stockholm County Council

  
  

  Work and interests

  Sven Bölte, Ph.D., is professor of child and adolescent psychiatric science at the Department of Women’s and Children’s Health, Karolinska Institutet (KI), and senior clinical psychologist at the Division of Child and Adolescent Psychiatry, Center for Psychiatry Research, Region Stockholm, Sweden. He is director of the KI Center of Neurodevelopmental Disorders (“KIND”), and editor in chief of the Scandinavian Journal of Child and Adolescent Psychology and Psychiatry, He is founder of the Scientific Society Autism Spectrum (wgas.org) and international ADOS and ADI-R trainer. For his work, he has received several recognitions, such as the ”Life Watch Nordiska Priset”, ”Årets Ljus” (Society Attention), Psynk award GNET” (Sweden’s Municipalities & Regions), Autism CRC (Australia) Achievement in Autism Research and ”Fellow of the International Society for Autism Research” (INSAR). Among his commissions of trust are appointments at the Swedish Research Council, the European Network of Hyperkinetic Disorders, the National Society Attention scientific board, the Swedish Autism and Asperger Society, the Swedish Psychiatry Foundation, Swedish National Board of Institutional Care, and the National Agency for Special Needs Education and Schools. Professor Bölte has 30 years of clinical research experience and has published more than 500 original articles, reviews, book chapters, assessment and intervention tools in the field of autism, ADHD, and other neurodevelopmental conditions, with > 32,000 citations (H-index 87).

  Declaration of potential conflict of interests

  Bölte discloses that he has in the last 3 years acted as an author, consultant or lecturer for Medice and Roche.
  He receives royalties for textbooks and diagnostic tools from Hogrefe, Kohlhammer and UTB. Bölte is shareholder in SB Education/Psychological Consulting AB and NeuroSupportSolutions International AB.

• Prof. Daniel Brandeis (Germany)

  Departments of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health Mannheim, and University of Zurich

  
  

  Work and interests

  Neurophysiology, multimodal brain mapping and imaging of developmental trajectories and plasticity in child and adolescent psychiatry, longitudinal and multicenter studies, disorder-specific and transdiagnostic pathophysiological brain mechanisms, state regulation, attention, inhibition, sleep and ADHD, reading acquisition and dyslexia, aggression, neuroscience based biomarkers for stratification and prediction, clinical translation into prevention and innovative personalized treatments, neurofeedback and biofeedback RCTs, metaanalyses, ecological assessment and treatment, imaging genetics, gene x environment interactions.

  Declaration of potential conflict of interests

  Served as an unpaid scientific committee member in a EU-funded neurofeedback trial.

• Prof. Jan K. Buitelaar (Netherlands)

  Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboudumc;
  Karakter Child and Adolescent Psychiatry

  
  https://pubmed.ncbi.nlm.nih.gov/?term=Buitelaar+J&sort=date&size=50
  https://en.wikipedia.org/wiki/Jan_K._Buitelaar
  
  

  Work and interests

  Jan Buitelaar is an emeritus professor of psychiatry and child and adolescent psychiatry at the Radboud University Medical Centre, and at the Donders Institute for Brain, Cognition and Behaviour in Nijmegen, The Netherlands. He has a strong clinical and research interest in neuropsychiatric disorders as ADHD, autism and impulsivity and aggression related disorders, and is involved in pharmacological, cognitive, clinical, genetic, and neuroimaging studies in these disorders. His current active research is focused on translational studies aiming to identify new molecular targets for ADHD and autism through matching preclinical models to human imaging genetics studies. His research is supported by numerous grants from the European Union, NIH, and from the Dutch Medical Research Council.

  Declaration of potential conflict of interests

  Jan K Buitelaar has been in the past 3 years a consultant to / member of advisory board of / and/or speaker for Takeda, Roche, Medice, Angelini, Neuraxpharm, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.

• Dr. Sara Carucci (Italy)

  Dept. Biomedical Sciences, Sect. Neuroscience & Clinical Pharmacology, University of Cagliari, Cagliari, Italy;
  Child & Adolescent Neuropsychiatry Unit, “A.Cao” Paediatric Hospital, “G.Brotzu”, Hospital Trust, Cagliari Italy

  
  

  Work and interests

  I am a Senior Consultant Child and Adolescent Neuropsychiatrist in the Child & Adolescent Neuropsychiatry Unit at the ASL Cagliari, Italy, with clinical experience in neuropsychiatric disorders with particular attention to neurodevelopmental conditions such as ADHD, Mood Disorders and Disruptive, Impulse-Control and Conduct Disorders.
  My main research activities are focused on the efficacy and safety of medications for children and adolescents in psychiatric disorders including ADHD and Conduct Disorder. In 2016 I completed my PhD program in Neuroscience on the long-term effects of Methylphenidate in ADHD children and adolescents at the University of Cagliari. I collaborated on several FP-7 projects on child and adolescent Mental Health, and I am currently involved in many no profit independent studies on ADHD and other neurodevelopmental disorder as well as in Industry-supported European registrative trials for innovative medications in paediatric psychopharmacology. I also have a special interest in implementing research knowledge into routine clinical practice with the aim to meet the needs of the young patients in the clinical real world.

  Declaration of potential conflict of interests

  SC reports collaboration on projects from the EU Seventh Framework Programme and on clinical trials sponsored by Lundbeck, Otsuka, Janssen-Cilag, Angelini and Acadia. She has also been speaker/consultant for Angelini, Medice, Ecupharma.

• Prof. David Coghill (Australia)

  Professor of Child and Adolescent Psychiatry, Royal Children’s Hospital Melbourne, Financial Markets Foundation, Chair of Developmental Mental Health, Departments of Paediatrics and Psychiatry

  
  https://findanexpert.unimelb.edu.au/profile/773808-dave-coghill
  
  

  Work and interests

  Professor Dave Coghill is the Financial Markets Foundation Chair of Developmental Mental Health at the University of Melbourne, Professor of Child and Youth Psychiatry at the Royal Children's Hospital Melbourne and Orygen Youth Health. He is the President of the Australian ADHD Professionals Association. Dave has a broad research portfolio focussed on ADHD and neurodevelopmental conditions with a particular focus on cognition, psychopharmacology, evidence based clinical pathways, and measurement-based care.

  Declaration of potential conflict of interests

  David Coghill has received research support and/or honoraria from Shire/Takeda, Medice, Novartis and Servier and royalties from Oxford University Press and Cambridge University Press.

• Prof. Samuele Cortese (United Kingdom)

  University of Southampton;
  The EAGG chair

  
  https://www.southampton.ac.uk/psychology/about/staff/sc6r14.page
  
  

  Work and interests

  Samuele Cortese MD, PhD is currently Full Professor of Child and Adolescent Psychiatry at the University of Southampton and Honorary Consultant Child and Adolescent Psychiatrist for Solent NHS Trust. He is also Adjunct Full Professor with the New York University (NYU) and Full Professor at the University of Bari, Italy. His research focuses on neurodevelopmental disorders, in particular ADHD. He is the chair of the European ADHD Guidelines Group. In 2022, he ranked #1 worldwide in terms of expertise on Attention-Deficit/Hyperactivity Disorder (ADHD) according to Expertscape.

  Declaration of potential conflict of interests

  Past 5 years: Samuele Cortese declares honoraria and reimbursement for travel and accommodation expenses for lectures from the following non-profit associations: Association for Child and Adolescent Central Health (ACAMH), Canadian ADHD Alliance Resource (CADDRA), British Association of Pharmacology (BAP), Meedice, and from Healthcare Convention for educational activity on ADHD.

• Prof. David Daley (United Kingdom)

  David Daley is Professor of Psychological Intervention and Knowledge Exchange and Head of Applied Psychological Practice within NTU Psychology, School of Social Science, Nottingham Trent University, Uk

  
  https://www.ntu.ac.uk/staff-profiles/social-sciences/david-daley
  
  

  Work and interests

  David Daley is Professor of Psychological Intervention and Knowledge Exchange and Head of Applied Psychological Practice within NTU Psychology, School of Social Science, Nottingham Trent University, Uk He received his B.A. in Applied Psychology from the National University of Ireland University College Cork and his Ph.D. in Developmental Psychopathology from the University of Southampton, UK.
  His research interests are focused on non-shared environmental influences on ADHD; in particular he has devoted much of his career to the study of factors that enhance and interfere with the effective and enjoyable parenting of children with ADHD. He is internationally recognized as an expert in the development and evaluation of psychological interventions for families of children with ADHD.

  Declaration of potential conflict of interests

  Professor Daley reports grants, personal fees, non-financial support and other from Shire/Takeda, and non-financial support from Medice, non-financial support from Qb Tech, other from Hachette in the form of royalities from the self help version of the New Forest Parent Training Programme and other from New Forest Parent Training Programme in form of fees for the provision of training and supervision in the New Forest Parent Training Programme.

• Prof. Dr. Manfred Döpfner (Germany)

  Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy; Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany;
  School of Child and Adolescent Cognitive Behavior Therapy (AKiP), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany;
  Department of Psychology, Faculty of Human Sciences, University of Cologne, Germany

  
  https://akip.uk-koeln.de/
  
  

  Work and interests

  Manfred Döpfner is director of the School for Child and Adolescent Cognitive Behavior Therapy at the University of Cologne. He is supervisor in cognitive behaviour therapy. He received the German Psychology Prize for his scientific work in 2005.
  His main research interests are assessment, prevention, and treatment of ADHD, Conduct Disorders, Anxiety Disorders, Obsessive Compulsive Disorders and Tic Disorders. He is principal investigator of several multicenter trials on the effects of prevention, cognitive behavior therapy (including self-help interventions and digital interventions), and pharmacotherapy for children with ADHD and other externalizing disorders.

  Declaration of potential conflict of interests

  Manfred Döpfner received consulting income and research support from Lilly, Medice, Takeda, and eyelevel GmbH and research support from the German Research Foundation, German Ministry of Education and Research, German Ministry of Health, and Innovation Fund. He received income as head, supervisor, and lecturer of the School of Child and Adolescent Cognitive Behaviour Therapy at the University Hospital Cologne and as consultant for Child Behaviour Therapy at the National Association of Statutory Health Insurance Physicians (Kassenärztliche Bundesvereinigung). He also received royalties from treatment manuals, books and psychological tests published by Beltz, Elsevier, Enke, Guilford, Hogrefe, Huber, Kohlhammer, Schattauer, Springer, Wiley.

• Dr. Maite Ferrin (United Kingdom)

  Barnet Enfield and Haringey NHS Trust and Recognition Health London, UK

  
  

  Work and interests

  Consultant Child and Adolescent Psychiatrist with special interest in psychoeducation of families of young people with ADHD.

  Declaration of potential conflict of interests

  Payment By Medice for presenting in conferences in 2019, 2021 and 2022 and by Rovi for conferences in 2020,2021 and 2022. Advisory board for Novartis in 2020. PI for Servier for Phase 3 study on Bumetanide for severe ASD.

• Prof. Dr. Cedric Galera (France)

  Université de Bordeaux, Bordeaux Population Health Center INSERM, Centre Hospitalier Perrens, Bordeaux, France

  
  

  Work and interests

  Cédric Galera is professor of Child and adolescent Psychiatry at the Bordeaux University Hospital. Doctor in epidemiology, he leads a research team dedicated to youth mental health at the Bordeaux Population Health Center (INSERM 1219).
  His work aims at (1) Understanding the risk and protective factors of Mental, Neurological and Substance use problems in young people using a lifespan perspective and (2) Test the efficacy of strategies to prevent Mental, Neurological and Substance use problems and build resilience to stressors in youths / parents.

  Declaration of potential conflict of interests

  N/A

• Prof. Chris Hollis (United Kingdom)

  Mental Health & Clinical Neuroscience, University of Nottingham & NIHR MindTech MedTech Co-Operative

  
  https://www.nottingham.ac.uk/medicine/people/chris.hollis
  
  

  Work and interests

  Chris Hollis is Professor of Child & Adolescent Psychiatry at the University of Nottingham, Director of the NIHR MindTech MedTech Co-operative and leads the NIHR Nottingham BRC Mental Health and Technology Theme. He is Principal Investigator on the HTA ORBIT (Online Remote Behavioural Intervention for Tics) trial (Hollis et al. Lancet Psychiatry. 2021 Oct; 8(10):871-882) and co-leads the £4M MRC programme award ‘Adolescent Mental Health in the Digital World’. He led the AQUA trial of QbTest for ADHD (Hollis et al. Journal of Child Psychology and Psychiatry. 2018 Dec;59(12):1298-1308) which is now supported by the National AHSN ADHD Focus Programme for widespread NHS adoption.
  
  Chris trained in psychiatry at the Maudsley Hospital and Institute of Psychiatry, where he was awarded an MRC Training Fellowship and completed his PhD on the long-term adult outcome adolescent-onset psychosis. He works as a Consultant in Developmental Neuropsychiatry with Nottinghamshire Healthcare NHS Foundation Trust and leads a regional lifespan neurodevelopmental service at Queen’s Medical Centre, Nottingham. His clinical and research interests include ADHD, Tourette syndrome, early onset schizophrenia and the development, evaluation and implementation of digital technologies to support better mental health.
  
  As Director of MindTech, Chris is passionate about harnessing digital technology and building its evidence-base in mental healthcare by bringing together patients, clinicians, academics and technology developers. In 2020, Chris was a contributor to the 2020 World Innovation Summit for Health (WISH) report: The digital mental health revolution: Transforming care through innovation and scale-up. He was the recipient of the Association of Child of Child & Adolescent Mental Health (ACAMH) Digital Innovation Award 2020. He recently led the James Lind Alliance priority Setting Partnership’s Top 10 research priorities for digital technology in mental healthcare (Hollis et al. Lancet Psychiatry. 2018 Oct;5(10):845-854). Chris chaired the NICE Guideline for schizophrenia and psychosis in children and young people (2011-13) and was a member of the 2018 NICE ADHD (Update) Guideline Committee. In 2015, Chris received a prestigious NIHR Senior Investigator Award. This distinguished accolade was awarded for a further 4 years in April 2019.

  Declaration of potential conflict of interests

  Member of the 2018 NICE ADHD (Update) Guideline Committee

• Prof. Martin Holtmann (Germany)

  LWL-University Hospital for Child and Adolescent Psychiatry, Ruhr-University Bochum

  
  

  Work and interests

  - ADHD: comorbidity with affective disorders and SUD;
  - non-pharmacological treatments for ADHD, affective disorders, and SUD;
  - clinical picture, course and treatment of bipolar disorder and severe mood dysregulation/DMDD

  Declaration of potential conflict of interests

  Martin Holtmann served in an advisory role for Shire, Takeda and Medice and received conference attendance support or was paid for public speaking by Medice, Shire and Neuroconn.
  He received research support from the German Research Foundation and the German Ministry of Education and Research.
  He received royalties as Editor-in-Chief of the German Journal for Child and Adolescent Psychiatry and for textbooks from Hogrefe.

• Prof. Jonna Kuntsi (United Kingdom)

  Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London

  
  

  Work and interests

  Jonna Kuntsi is Professor of Developmental Disorders and Neuropsychiatry at the Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London. She first joined the Centre as a Lecturer, following training (BSc, MSc, PhD) and positions at University College London and the Great Ormond Street Hospital for Children. Her research focuses on ADHD and other conditions and traits that often co-occur with ADHD. A major focus currently is the ADHD Remote Technology (ART) research programme, for which Jonna and team have received £4 million funding from the UK Medical Research Council and European Commission for projects on a range of topics (e.g. ADHD transition; cardiometabolic risk factors and medication adherence in adults with ADHD). In addition to being EUNETHYDIS Co-Chair, she is on the steering committee/Principal Investigator in several other international research networks, including the International Multi-centre Persistent ADHD Collaboration ‘IMpACT’, the ECNP ADHD across the Lifespan Network and the ECNP Digital Health Applied to the Clinical Research of Brain Disorders Network. She actively collaborates with patient support organisations, including ADHD Europe and the UK ADHD Information and Support Service (ADDISS), and with SMEs, such as Empatica and The Hyve.

  Declaration of potential conflict of interests

  Jonna Kuntsi has given talks at educational events sponsored by Medice; all funds are received by King’s College London and used for studies of ADHD.

• Dr. Peter Nagy (Hungary)

  Division of Neurodevelopmental Disorders, Bethesda Children's Hospital, Budapest, Hungary

  
  

  Work and interests

  I have been fascinated with child psychiatry ever since I first heard about it. My first job after completing medical school was at Hungary’s only dedicated child psychiatric clinic, which was the first place in the country to begin offering comprehensive services to children with Tourette’s syndrome. Tourette’s was the first neurodevelopmental disorder I encountered as a young doctor, and I was amazed by the interplay of the infinitely complex central nervous system and the environment. Later, my work and therefore my experience expanded to other neurodevelopmental disorders, most notably, ADHD. When several years later, I became the director of this clinic, I made it a top priority to add quality research to patient care, and we participated in many national and international studies on ADHD, Tourette’s, OCD, and ASD. After 8 years in management, I decided to focus all my time on clinical work and research, so I switched jobs and now I am chief of the neurodevelopmental unit at Bethesda Children’s Hospital, Budapest, Hungary.

  Declaration of potential conflict of interests

  I have received occasional remuneration to serve on the advisory board for Eli Lilly and Co. and MEDICE Arzneimittel Pütter GmbH & Co. I have participated in clinical studies focusing on various neurodevelopmental disorders funded by pharmaceutical companies (Shire, Otsuka, Servier).

• Prof. Diane Purper-Ouakil (France)

  University Hospital of Montpellier, Department of Child and Adolescent Psychiatry, University of Montpellier;
  CEAND, INSERM U 1018 UVSQ, Psychiatry, Development and Trajectories

  
  

  Work and interests

  Diane Purper-Ouakil is a Professor of child and adolescent psychiatry at the University Hospital of Montpellier, France. She has been head of the child and adolescent unit of the Saint Eloi Hospital since 2011. This unit has inpatient and outpatient care facilities for young patients with different mental health conditions and has specialized services for ADHD, trauma-related and eating disorders. Diane Purper-Ouakil is the president of the newly founded French Society of ADHD, an organisation for health professionals involved in clinical practice, optimisation of care trajectories and research. She has recently joined the steering committee of Eunethydis and is also the co-lead of the ECNP child and adolescent network. Diane Purper-Ouakil aims to develop the evidence base of psychological, neurophysiological and pharmacological treatments, especially for children and adolescents with challenging and enduring behavioural and emotional symptoms. She is involved in treatment studies assessing several types of interventions. Her current research focuses on parent programs, innovations in healthcare trajectories, and digital interventions, that can contribute to comprehensive treatment plans for young people with complex needs.

  Declaration of potential conflict of interests

  01/2019 speaker fee from Shire, unpaid scientific collaboration with Mensia (scientific coordination of the Newrofeed study)
  02/2019-02/2022 non-financial support from HAC Pharma, Medice, Lundbeck SAS

• Prof. J. Antoni Ramos-Quiroga (Spain)

  Department of Psychiatry at Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain;
  Department of Psychiatry and Legal Medicine, Barcelona Autonomous University, Barcelona, Spain;
  Vall d’Hebron Research Institute (VHIR) , Barcelona, Spain

  
  https://www.doctorramosquiroga.com/
  https://hospital.vallhebron.com/es/profesionales/josep-antoni-ramos-quiroga
  
  

  Work and interests

  Professor Ramos-Quiroga (orcid: 0000-0003-1622-0350), has published more than 270 articles in the field of genetics, psychopharmacology, neurodevelopmental disorders and depression (h-index: 57 and more than 16,500 citations). He is also VHIR’s Principal Investigator in seven European grants (Horizon 2020) focused on treatment-resistant depression, ADHD and autism. Dr. Ramos-Quiroga was one of the founders of International Collaboration on ADHD and Substance Abuse (ICASA) and he is member of the board of ICASA Foundation. Also, he is member of several international consortiums focused on mood disorders and neurodevelopmental disorders (IMpACT, PGC, ENIGMA, ADHD-ECNP Network).

  Declaration of potential conflict of interests

  J.A.R.Q was on the speakers’ bureau and/or acted as consultant for Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen- Cilag, Shire, Oryzon, Roche, Psious, and Rubió.

• Prof. Marcel Romanos (Germany)

  University Hospital Würzburg, Center of Mental Health, Dep. of Child and Adolescent Psychiatry, Psychosomatics Psychotherapy, Würzburg, Germany

  
  https://www.ukw.de/child-and-adolescent-psychiatry-psychotherapy-and-psychosomatics/research/
  
  

  Work and interests

  My initial interest in ADHD research was on genetics and neurobiology by investigateing large pedigrees with high density of ADHD. Aiming to translate neurobiological findings to clinical service I evaluated putative biomarkers of ADHD and participated in large multicenter therapy studies. Recently my focus broadened with respect to assessing the quality and availability of clinical services. I have established a longstanding relationship with the German ADHD self-help organization. Apart fron ADHD my research interests pertain to anxiety disorders and evidence-based prevention mental disorders in childhood and adolescence.

  Declaration of potential conflict of interests

  Within the last 10 years I have not had any direct or indirect financial relation with the pharma-industry. I have contributed as writer and editor to ADHD psychotherapy manuals and psychopharmacology books. My research is funded by official agencies such as the DFG, BMBF, Innvationsfonds, Ministries etc. I am member of several organizations and associations, e.g. president-elect of the German Association of Child and Adolescent Psychiatry.

• Prof. Paramala J. Santosh (United Kingdom)

  Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King’s College London;
  South London & Maudsley NHS Foundation Trust

  
  https://kclpure.kcl.ac.uk/portal/en/persons/paramala.1.santosh
  
  

  Work and interests

  Professor Paramala Santosh is a Consultant Child & Adolescent Psychiatrist at the Maudsley Hospital, and a Professor in Developmental Neuropsychiatry and Psychopharmacology at the Institute of Psychiatry, Psychology & Neurosciences (IoPPN), King's College London. He developed and heads the national and specialist Centre for Interventional Paediatric Psychopharmacology and Rare Diseases (CIPPRD), and the CIPP Rett Centre. The CIPP Rett Centre is the world's first centre for personalised medicine in Rett Syndrome that focuses on developing digital health strategies to monitor and manage patients whilst conducting translational research using the HealthTrackerTM platform, providing holistic specialist care, and conducting clinical trials. Professor Santosh also co-developed the GDPR compliant HealthTrackerTM platform for remote screening, patient reported outcome monitoring, and structured medication review and is the CEO of the SME HealthTracker Ltd. Professor Santosh is an internationally recognised expert in ADHD, ASD, paediatric psychopharmacology, treatment-resistant developmental multimorbidity, and neuropsychiatric problems in acquired brain injury, childhood dementias, and rare diseases such as Rett syndrome, Septo-Optic Dysplasia, Mucopolysaccharidoses, and paediatric neurodegeneration. His research focusses on translational personalised medicine approaches using remote digital health monitoring, structured pharmacological approaches, sensor-based psychophysiological monitoring, and machine learning.

  Declaration of potential conflict of interests

  Professor Santosh is the co-inventor of the HealthTrackerTM and is the Chief Executive Officer and shareholder in HealthTracker Ltd.

• Prof. Emily Simonoff (United Kingdom)

  Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King’s College London

  
  https://kclpure.kcl.ac.uk/portal/emily.simonoff.html
  
  

  Work and interests

  Emily Simonoff is Professor of Child and Adolescent Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, King's College London, where she is also head of the Department. She is also academic lead for the Child and Adolescent Mental Health Services Clinical Academic Group at the South London and Maudsley Foundation Trust. She in a UK National Institute of Health Research Senior Investigator. She was the Senior Clinical Advisor to the National Institute of Health and Clinical Excellence (NICE) on the 2018 ADHD guidelines and is currently a member of the ICHOM Standard Set for Neurodevelopmental Disorders Advisory Group. She chairs the EAGG since 2015. Emily's interests span a range of neurodevelopmental disorders. She has also been a member of the two NICE Guidelines groups for autism and a member of the Strategy Board for the UK National Autism Project. She has been a member of the Westminster Commission for Autism and has given evidence to the All-Party Parliamentary Group on Autism. Emily receives research funding related to autism from the Medical Research Council, Economic and Social Research Council, National Institute of Health and Research EU Innovative Medicines Initiative, amongst other organization. She is a consultant child and adolescent psychiatrist in the Maudsley-based Service for Complex Autism and Associated Neurodevelopmental Disorders, funded by NHS England to see children and young people across the southern region with complex presentations.

  Declaration of potential conflict of interests

  Grant funding over the last 5 years from the K National Institute for Health Research, Medical Research Council, Economic and Social Research Council, Charity, Mudsley Charity and the European Union Innovative Medicines Initiative.
  
  Simonoff has developed the app Molehill Mountain for the management of anxiety in autistic people.

• Prof. Edmund Sonuga-Barke (United Kingdom)

  Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King’s College London

  
  https://www.kcl.ac.uk/people/edmund-sonuga-barke
  
  

  Work and interests

  Sonuga-Barke is an academic developmental psychologist (non-clinician) and currently Professor of Developmental Psychology, Psychiatry and Neuroscience at the Institute of Psychology, Psychiatry and Neuroscience, Kings College London. He is Honorary Skou Professor at Aarhus University School of Medicine, Denmark. He is Editor-in-Chief of the Journal of Child Psychology and Psychiatry.
  
  Motivated by his own experience as a child growing up with learning difficulties his research focuses on improving the lives of children and adolescents with neuro-developmental disorders - especially ADHD. To this end, his work aims to develop new therapeutic approaches by employing basic developmental science approaches to study the pathogenesis of such conditions, their underlying genetic and environmental risk and resilience sources and their mediating brain mechanisms and developmental and mental health outcomes.
  
  He has led the series of EAGG meta-analyses of non-pharmacological approaches to ADHD treatments.
  
  Sonuga-Barke is a Fellow of the Academy of Medical Sciences (2016) and The British Academy (2018).

  Declaration of potential conflict of interests

  In the last three years he has given paid talks for Medice and Shire(Takida). He has been a consultant for Neurotech Solutions International. He currently holds grant funding from QBTech. He receives an annual honorarium from the JCPP.

• Prof. Dr. Cesar Soutullo (USA)

  John S. Dunn Endowed Professor;
  Director, ADHD Outpatient Program;
  Louis A. Faillace MD Department of Psychiatry & Behavioral Sciences;
  McGovern Medical School, The University of Texas Health Science Center at Houston, Texas, USA

  
  https://www.ncbi.nlm.nih.gov/pubmed/?term=Soutullo+C
  https://scholar.google.com/citations?hl=es&user=No-3YcMAAAAJ
  https://med.uth.edu/psychiatry/2022/11/11/cesar-a-soutullo-md-phd/
  
  

  Work and interests

  Child & Adolescent Psychopharmacology and Phenomenology of ADHD an Mood disorders.
  Early detection and treatment optimization, adherence and maintenance of full response in children and adolescents with ADHD.
  Mentoring & teaching students, residents, fellows, nurses, social worker, etc in an interdisciplinary team.

  Declaration of potential conflict of interests

  2021-2024:
  Departmental Research funds (non-personal):
  • ARPA. American Recovery Plan Act - USA
  • John S. Dunn Foundation
  • Texas Child Mental Health Care Consortium (Youth Depression & Suicide Network) SB11
  • The Favrot Fund
  • Vivian L. Smith Foundation
  Consultant / Advisory Board:
  • Big Health DSMB - USA
  • Inno-sphere - Germany
  • NeuroTech Solutions Ltd - Israel
  • Limbix Health DSMB - USA
  Speaker's Bureau / CME talks (not about a product):
  • Cuquerella Medical Consulting - Spain
  • Bial - Portugal
  • Medice - Germany
  • Rubio – Spain
  • Tecnofarma - Peru
  Royalties:
  • Editorial Médica Panamericana - Spain
  

• Prof. Hans-Christoph Steinhausen (Switzerland)

  Department of Child and Adolescent Psychiatry, Psychiatric University Hospital Zurich, Switzerland

  
  https://www.kjpd.uzh.ch/de/aboutus/Geschichte/Ehemalige-%C3%84rztliche-Direktoren.html
  
  

  Work and interests

  Developmental psychopathology and epidemiology, neuropsychiatry and genetics, clinical psychopharmacology, evaluation research.

  Declaration of potential conflict of interests

  In the last 36 months, H.-C. Steinhausen has worked as a speaker for Medice and has received book royalties from Cambridge University Press, Elsevier, Hogrefe, Huber, Klett, and Kohlhammer publishers.

• Prof. Argyris Stringaris (United Kingdom)

  Department of Epidemiology and Applied Clinical Research, Division of Psychiatry, University College London, London, UK;
  Section of Clinical and Computational Psychiatry (Comp), Emotion and Development Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA

  
  

  Work and interests

  I am the Professor of Child and Adolescent Psychiatry at UCL and head the Mood in Neurodevelopment (MIND) Unit at UCL. As a Clinician Scientist, I study mood and the mechanisms that lead to depression, particularly in adolescents. I am learning from my patients, my colleagues, but also from disciplines outside my own, such as philosophy, history, computer science and neurology. My clinical interest is in depression and severe irritability (emotion dysregulation).
  I was until recently Senior Investigator and Chief of the Section of Clinical and Computational Psychiatry at NIMH/NIH in the USA and before that a Senior Lecturer and a Wellcome Trust Fellow at the Institute of Psychiatry Psychology and Neuroscience, King's College London. I trained in Child and Adolescent Psychiatry at the Maudsley Hospital. I am the President of the International Society for Research in Child and Adolescent Psychiatry.
  Recent insights from our laboratory include:
  • How the timing of events influences the way we feel
  • The Phenomenon of Passage of Time Dysphoria and how it affects psychological tasks.
  • The limited ability of MRI to predict suicidality in young people.
  • Use of magnetoencephalography to describe reward and mood dynamics in the brain.
  • How to treat severe irritability in youth.
  I am also very excited about our current and upcoming work on:
  • How power relationships shape emotional responses.
  • Statistical approaches to capturing adolescents’ preferences for treatment.
  

  Declaration of potential conflict of interests

  Professor Stringaris' research influenced the DSM-5 decisions on dimensions of ODD and the recognition of irritability as a source of impairment in children and adolescents. He has developed the Affective Reactivity Index a measure of irritability with colleagues from KCL and NIH. He was also co-developer of the Coronavirus Impact Survey (CRISIS), a measure of the effects of the covid pandemic on mental and physical health. 
  He is an Editor for European Child and Adolescent Psychiatry, a former Associate Editor of Journal of Child Psychology and Psychiatry, President of the International Society for Child and Adolescent Psychopathology. One of his most recent projects involved the co-development with Dr Hanna Keren  of a mood-machine interface device to modulate mood states.

• Prof. Anita Thapar (United Kingdom)

  Department of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University

  
  https://www.cardiff.ac.uk/people/view/126769-thapar-anita
  
  

  Work and interests

  I conduct epidemiological, genetic and clincal research on ADHD and additional neurodevelopmental disorders (e.g. autism spectrum disorder) as well as depression from 0 to 25 years.

  Declaration of potential conflict of interests

  N/A

• Prof. Dr. Barbara J. van den Hoofdakker (Netherlands)

  University of Groningen, University Medical Center Groningen, Department of Child and Adolescent Psychiatry, Groningen, The Netherlands;
  Accare Child Study Center, Groningen, The Netherlands;
  University of Groningen, Department of Clinical Psychology and Experimental Psychopathology, Groningen, The Netherlands
  

  
  

  Work and interests

  I work as a special professor and clinical psychologist at Accare, a large Dutch child and adolescent mental health and research organization, and at the University of Groningen (Departments of Child and Adolescent Psychiatry and of Clinical Psychology and Experimental Psychopathology ). I am head of the post-master education program for psychologists in training for health care psychologist and acting head of the post-master education program for health care psychologists in training for clinical psychologist. My research and clinical interests focus on behavioral treatments for children with behavioral problems, including ADHD. I am actively working on the dissemination of scientific insights into practice and a member of Dutch ADHD guideline and practice standard groups. In the past years I was involved in the Psychosocial ADHD Interventions (PAINT) research group. The research of the PAINT group focusses on effective components of behavioral interventions, moderators of behavioral treatment response by conducting individual participant data meta analyses, and effectiveness of brief parent and teacher training programs for children with behavioral problems.

  Declaration of potential conflict of interests

  Received research grants from ZonMw (The Netherlands Organisation for Health Research and Development); NWO (The Netherlands Organisation for Scientific Research); UMCG (University Medical Centre Groningen, The Netherlands).
  Receives royalties as one of the editors of "Sociaal Onhandig" (published by Van Gorcum), a Dutch book for parents that can be used in parent training. Non-financial: is and has been involved in the development and evaluation of several behavioral interventions, without financial interests; has been a member of Dutch ADHD guideline groups; is an advisor of the Dutch Knowledge Centre for Child and Adolescent Psychiatry.

• Prof. Saskia van der Oord (Belgium)

  Faculty of Psychology and Educational Sciences, KU Leuven

  
  http://lirias.kuleuven.be/cv?Username=U0062158
  
  

  Work and interests

  Prof. Dr. Saskia van der Oord research is focused on ADHD in children and adolescents. Her research is focused on 1) improving effectiveness of current behavioral treatments by knowing more of effective treatment elements and for whom treatment works most 2) integrating knowlegde of experimental research of motivation and learning in ADHD into treatment 2) developing new treatments for ADHD (e.g. a sleep focused treatment for adolescents with ADHD) and experimentally testing these on effectiveness 3) reducing stigma for ADHD by (game-based )ADHD awareness interventions. She works as a clinical child psychologist/behavior therapist and supervises postmaster clinical psychology students in the Faculty’s assessment and intervention facility Praxis P. Also, she is head of the 4-year postmaster child and adolescent behavior therapy training.

  Declaration of potential conflict of interests

  N/A

• Prof. Ian C. K. Wong (United Kingdom)

  Department of Pharmacology and Pharmacy, The University of Hong Kong

  
  https://www.pharma.hku.hk/Our-People/Professoriate/Head/Professor-Ian-CK-WONG/Professor-Ian-CK-WONG-Profile
  
  

  Work and interests

  Professor Ian Wong has worked on the safety of psychotropic drugs since 1997. He has been highly successful in his application for research funding from the Hong Kong Government and European Commission, amounting to several million pounds for psychopharmacology research. He has over 600 publications. Professor Wong has supervised more than 20 PhD students who investigated the safety of psychotropic drugs for the treatment of ADHD, anorexia, ASD, bipolar disorder, psychosis, and depression. He has particular expertise in interrogating national and international healthcare databases, using sophisticated strategies that enable high-quality evidence-based information to be obtained. This has enabled him to have a significant impact in improving the safety and efficacy of the treatment of psychiatric disorders. Three recent examples of publications using these strategies with analysis of large databases were the Lancet Psychiatry paper showing wide variations in psychotropic drug prescribing across 65 countries and regions and recommending future improvement in practice and research for some lower-middle-income countries. His papers in the Lancet Child and Adolescent Health and JAMA Psychiatry showing that first-line medication for attention deficit hyperactivity disorder (methylphenidate) does not cause epilepsy or increased risk in suicidal behaviour. His BMJ and JAMA Internal Medicine papers showing that antidepressants and antipsychotic treatment during pregnancy does not increase the risk of attention deficit hyperactivity disorder in the offspring. Professor Ian Wong has developed a commercially available medicinal product for the treatment of acute prolonged seizures (Buccolam) via his spin-off company with the UCL and Great Ormond Street Hospital for Children. Buccolam is now used by patients with epilepsy throughout Europe. Last but not least, Professor Wong received commendation from the Chief Executive of Hong Kong SAR Government in 2022 for his contribution to the fighting against COVID-19 pandemic in Hong Kong.

  Declaration of potential conflict of interests

  I have received research and educational grants from Amgen, Bayer, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund, the National Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia.
  I was a member of NICE ADHD Guideline Development Group in England.

• MD. Prof. Alessandro Zuddas (Italy)

  University of Cagliari, Dept Biomedical Sciences, Sect. Neuroscience & Clinical Pharmacology, Cagliari, Italy
  Child & Adolescent Neuropsychiatry, "A.Cao" Pediatric Hosptal, Cagliari

  
  https://www.unica.it/unica/page/en/alessandro_zuddas
  
  

  Work and interests

  Alessandro Zuddas, MD, is currently Professor of Child Neuropsychiatry at the School of Medicine, University of Cagliari and Director of the Child & Adolescent Neuropsychiatry Unit a the “A.Cao” Paediatric Hospital, Cagliari, Italy.
  His work integrates Developmental Psychopathology and Child & Adolescent Psychopharmacology approaching the study of the biological mechanism of neuro-developmental and mental health conditions in order to develop and validate innovative therapeutical strategies.
  Main areas of interest are ADHD and other developmental disorders as well as Affective and conduct disorders.
  He also coordinate the European Child & Adolescent Psychopharmacolgy Network (ECAPN) at EnprEMA.

  Declaration of potential conflict of interests

  Prof. Zuddas reported personal fees for being on advisory boards from Angelini, Servier, and Shire/Takeda; research grants from Acadia, Angelini, Janssen, Lundbeck, Otsuka, and Servier; and royalties from Giunti OS, Hogrefe Editore, and Oxford University Press.

Publications

• Santosh P., Cortese S., Hollis C., Bölte S., Daley D., Coghill D., Holtmann M., Sonuga-Barke E. J. S., Buitelaar J., Banaschewski T., Stringaris A., Döpfner M., Van der Oord S., Carucci S., Brandeis D., Nagy P., Ferrin M., Baeyens D., van den Hoofdakker B. J., Purper-Ouakil D., Ramos-Quiroga A., Romanos M., Soutullo C. A., Thapar A., Wong I. C. K., Zuddas A., Galera C., Simonoff E. (2023). Remote assessment of ADHD in children and adolescents: recommendations from the European ADHD Guidelines Group following the clinical experience during the COVID-19 pandemic. Eur Child Adolesc Psychiatry 32, 921–935. doi: 10.1007/s00787-023-02148-1.
• Westwood S.J., Parlatini V., Rubia K., Cortese S., Sonuga-Barke E.J.S., European ADHD Guidelines Group (EAGG) (2023). Computerized cognitive training in attention-deficit/hyperactivity disorder (ADHD): a meta-analysis of randomized controlled trials with blinded and objective outcomes. Mol Psychiatry 28, 1402–1414, doi: 10.1038/s41380-023-02000-7
• Coghill, D., Banaschewski, T., Cortese, S., Asherson P., Brandeis D., Buitelaar J., Daley D., Danckaerts M., Dittmann R.W., Doepfner M., Ferrin M., Hollis C., Holtmann M., Paramala S., Sonuga-Barke E., Soutullo C., Steinhausen H-C., Van der Oord S., Wong I.C.K., Zuddas A., Simonoff E. (2021). The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry 32, 1337–1361, doi: 10.1007/s00787-021-01871-x.
• Cortese S., Coghill D., Santosh P., Hollis C., Simonoff E., European ADHD Guidelines Group (2020). Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. Lancet Child Adolesc Health 2020, Volume 4, Issue 6, e15, doi: 10.1016/S2352-4642(20)30144-9.
• Cortese S., Asherson P., Sonuga-Barke E., Banaschewski T., Brandeis D., Buitelaar J., Coghill D., Daley D., Danckaerts M., Dittmann RW., Doepfner M., Ferrin M., Hollis C., Holtmann M., Konofal E., Lecendreux M., Santosh P., Rothenberger A., Soutullo C., Steinhausen HC., Taylor E., Van der Oord S., Wong I., Zuddas A., Simonoff E., for the European ADHD Guidelines Group (2019). ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. Lancet Child Adolesc Health 2020, Volume 4, Issue 6, Pages 412-414, doi: 10.1016/S2352-4642(20)30110-3.
• Wong ICK, Banaschewski T, Buitelaar J, Cortese S, Döpfner M, Simonoff E, Coghill D; European ADHD Guidelines Group. (2019). Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. Lancet Psychiatry. 2019;6(6):528‐537. doi:10.1016/S2215-0366(19)30096-3. PubMed PMID: 31122482.
• Cipriani A, Adamo N, Giovane CD, Coghill D, Banaschewski T, Hollis C, Zuddas A, Simonoff E, Cortese S (2018). Unbalanced risk-benefit analysis of ADHD drugs – Authors’ reply. Lancet Psychiatry. 2018;5(11):871‐873. doi:10.1016/S2215-0366(18)30396-1. PubMed PMID: 30401441.
• Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727‐738. doi:10.1016/S2215-0366(18)30269-4. PubMed PMID: 30097390; PubMed Central PMCID: PMC6109107.
• Cortese S, Adamo N, Mohr-Jensen C, Hayes AJ, Bhatti S, Carucci S, Del Giovane C, Atkinson LZ, Banaschewski T, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A, Coghill D; European ADHD Guidelines Group (EAGG). (2017). Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. BMJ Open. 2017 Jan 10;7(1):e013967. doi: 10.1136/bmjopen-2016-013967. PubMed PMID: 28073796; PubMed Central PMCID: PMC5253538.
• Daley D., Van der Oord S., Ferrin M., Cortese S., Danckaerts M., Doepfner M., et al. (2017). Practitioner review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with ADHD. Journal of Child Psychology and Psychiatry, 59: 932-947.
• Banaschewski T., Buitelaar J., Chui C.S.L., Coghill D., Cortese S., Simonoff E., et al. (2016). Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater. Evidence Based Mental Health, 19: 97-99.
• Cortese S, Brandeis D, Holtmann M, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). (2016). The European ADHD Guidelines Group replies. J Am Acad Child Adolesc Psychiatry. 2016 Dec;55(12):1092-1093. doi: 10.1016/j.jaac.2016.09.492. PubMed PMID: 27871646.
• Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, Santosh P, Simonoff E, Stevenson J, Stringaris A, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). (2016). Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):444-55. doi: 10.1016/j.jaac.2016.03.007. Epub 2016 Apr 1. Review. PubMed PMID: 27238063.
• Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW, Holtmann M, Santosh P, Stevenson J, Stringaris A, Zuddas A, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). (2015). Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):164-74. doi: 10.1016/j.jaac.2014.12.010. Epub 2014 Dec 29. Review. Erratum in: J Am Acad Child Adolesc Psychiatry. 2015 May;54(5):433. PubMed PMID: 25721181; PubMed Central PMCID: PMC4382075.
• Daley D, van der Oord S, Ferrin M, Danckaerts M, Doepfner M, Cortese S, Sonuga-Barke EJ; European ADHD Guidelines Group. (2014). Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):835-47, 847.e1-5. doi: 10.1016/j.jaac.2014.05.013. Epub 2014 Jun 26. Review. PubMed PMID: 25062591.
• Stevenson J, Buitelaar J, Cortese S, Ferrin M, Konofal E, Lecendreux M, Simonoff E, Wong IC, Sonuga-Barke E. (2014). Research review: the role of diet in the treatment of attention-deficit/hyperactivity disorder–an appraisal of the evidence on efficacy and recommendations on the design of future studies J Child Psychol Psychiatry. 2014 May;55(5):416-27. doi: 10.1111/jcpp.12215. Epub 2014 Feb 19. Review. PubMed PMID: 24552603
• Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J; European ADHD Guidelines Group. (2013). Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents J Child Psychol Psychiatry. 2013 Mar;54(3):227-46. doi: 10.1111/jcpp.12036. Epub 2013 Jan 7. Review. PubMed PMID: 23294014.
• Sonuga-Barke E, Brandeis D, Cortese S, Daley D, Danckaerts M, Döpfner M, Ferrin M, Holtmann M, Van der Oord S; European ADHD Guidelines Group. (2013). Response to Chronis-Tuscano et al. and Arns and Strehl Am J Psychiatry. 2013 Jul;170(7):800-2. doi: 10.1176/appi.ajp.2013.13020208r. PubMed PMID: 23820834.
• Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Döpfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC, Sergeant J; European ADHD Guidelines Group. (2013). Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments Am J Psychiatry. 2013 Mar;170(3):275-89. doi: 10.1176/appi.ajp.2012.12070991. Review. PubMed PMID: 23360949.
• Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E; European Guidelines Group. (2011). European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. doi: 10.1007/s00787-010-0140-6. Epub 2010 Nov 3. PubMed PMID: 21042924; PubMed Central PMCID: PMC3012210
• Sergeant JA, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Döpfner M, Rothenberger A, Santosh P, Sonuga-Barke EJ, Steinhausen HC, Taylor E, Zuddas A (2010). Eunethydis: a statement of the ethical principles governing the relationship between the European group for ADHD guidelines, and its members, with commercial for-profit organisations. Eur Child Adolesc Psychiatry. 2010 Sep;19(9):737-9. doi: 10.1007/s00787-010-0114-8. Epub 2010 Jun 12. Erratum in: Eur Child Adolesc Psychiatry. 2010 Sep;19(9):743. Buitelar, Jan [corrected to Buitelaar, Jan]. PubMed PMID: 20549526; PubMed Central PMCID: PMC3128714.
• Banaschewski T, EUNETHYDIS Guidelines Group (2008). [Joint position of the Guideline Group of the European Network for Hyperkintetic Disorders (EUNETHYDIS) and theGerman Central ADHD Network for ECG Recording on methylphenidate prescriptions] Z Kinder Jugendpsychiatr Psychother. 2008 Nov;36(6):437-9. doi:10.1024/1422-4917.36.6.437. German. PubMed PMID: 19034859
• Sergeant J (2004). EUNETHYDIS — searching for valid aetiological candidates ofAttention-Deficit Hyperactivity Disorder or Hyperkinetic Disorder Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I43-9. PubMed PMID: 15322956.
• Taylor E., Dopfner M., Sergeant J., Asherson P., Banaschewski T., Buitelaar J., et al. (2004). European clinical guidelines for hyperkinetic disorder – first upgrade. European Child & Adolescent Psychiatry, 13 Suppl 1: 7-30.
• Sergeant J, Steinhausen HC (1992). European perspectives on hyperkinetic disorder Eur Child Adolesc Psychiatry. 1992 Jan;1(1):34-41. doi: 10.1007/BF02084432. PubMed PMID: 29871402.

Former member

• MD. Prof. Alessandro Zuddas (Italy)

  University of Cagliari, Dept Biomedical Sciences, Sect. Neuroscience & Clinical Pharmacology, Cagliari, Italy
  Child & Adolescent Neuropsychiatry, "A.Cao" Pediatric Hosptal, Cagliari

  
  https://www.unica.it/unica/page/en/alessandro_zuddas
  
  

  Work and interests

  Alessandro Zuddas, MD, is currently Professor of Child Neuropsychiatry at the School of Medicine, University of Cagliari and Director of the Child & Adolescent Neuropsychiatry Unit a the “A.Cao” Paediatric Hospital, Cagliari, Italy.
  His work integrates Developmental Psychopathology and Child & Adolescent Psychopharmacology approaching the study of the biological mechanism of neuro-developmental and mental health conditions in order to develop and validate innovative therapeutical strategies.
  Main areas of interest are ADHD and other developmental disorders as well as Affective and conduct disorders.
  He also coordinate the European Child & Adolescent Psychopharmacolgy Network (ECAPN) at EnprEMA.

  Declaration of potential conflict of interests

  Prof. Zuddas reported personal fees for being on advisory boards from Angelini, Servier, and Shire/Takeda; research grants from Acadia, Angelini, Janssen, Lundbeck, Otsuka, and Servier; and royalties from Giunti OS, Hogrefe Editore, and Oxford University Press.

Our dear friend and colleague Prof Alessandro Zuddas was a very well respected member of EAGG. Very sadly, he passed away in July 2022.